Screener
Ionis Pharmaceuticals IONS Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Long-term obligations | 28,435 | 28,118 |
| Total liabilities | 2,554,764 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,311,837 | 3,145,402 |
| Accumulated other comprehensive loss | (33,897) | (25,281) |
| Accumulated deficit | (2,838,369) | (2,631,195) |
| Total stockholders' equity | 439,737 | 489,089 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's common stock, par value (in dollars per share)?
- Ionis Pharmaceuticals (IONS) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
- How has Ionis Pharmaceuticals's common stock, par value (in dollars per share) changed year-over-year?
- Ionis Pharmaceuticals's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Ionis Pharmaceuticals's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Ionis Pharmaceuticals's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude